Hims & Hers Stock Rises on Novo Nordisk Deal, But Analysts Hold Back on Buy Recommendation

Hims & Hers Inc. (HIMS) experienced a notable stock surge following the disclosure of a new commercial partnership with global pharmaceutical leader Novo Nordisk. Under the agreement, HIMS will integrate Novo Nordisk’s GLP-1-based weight management treatments into its digital health platform, targeting patients seeking accessible, prescription-driven solutions. The collaboration aims to accelerate patient onboarding and improve treatment adherence through HIMS’ telehealth infrastructure. Despite the positive catalyst, equity analysts have maintained a cautious stance, citing HIMS’ current valuation metrics and uncertain revenue contribution from the partnership in the near term. The company’s price-to-sales ratio exceeds 5.2x, well above the healthcare technology sector average of 3.8x, suggesting potential overvaluation relative to growth expectations. Additionally, HIMS reported a 12% year-over-year revenue decline in Q4 2025, underscoring ongoing challenges in customer acquisition and retention. The broader market reacted with measured enthusiasm. The Technology Select Sector SPDR Fund (XLK) rose 0.7% on the day, while the Health Care Select Sector SPDR Fund (VHT) edged up 0.3%, indicating sector-wide interest in digital health innovation but not a broad conviction in HIMS’ immediate trajectory. The Novo Nordisk deal is expected to contribute incremental revenue of up to $15 million in 2026, according to internal projections, but this represents less than 8% of HIMS’ projected annual revenue. Investors are watching for operational improvements, particularly in gross margin expansion and platform scalability, before shifting from a speculative to a core holding. The stock remains under pressure from high burn rates and competitive dynamics in the telehealth space, where companies like Teladoc and Amwell have maintained stronger cash flow stability.